EUVIMEDOdkrijte EUVIMED
Open access · CC BY-NC-ND 4.0

A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth

Sara Hellström iD, Andrea Jonsdotter, Maria Jonsson iD, Karin Pettersson, Sissel Saltvedt, Andreas Herbst, Johan Ågren, Ulrika Ådén, Magnus Domellöf, Henrik Hagberg, Ylva Carlsson iD

Acta Obstetricia et Gynecologica Scandinavica · 2023

DOI: 10.1111/aogs.14673 ↗

At a glance

Journal article in Acta Obstetricia et Gynecologica Scandinavica, 2023. Written by Sara Hellström and 10 co-authors. Institution: Department of Obstetrics and Gynecology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden. Major MEDLINE topics: Premature Birth, Cerebral Palsy, Neuroprotective Agents. Cited 10 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Frimurarfonden Barnhusdirektionen Foundation, Linnea and Josef Carlsson Foundaton, Rune and Ulla Almlövs stiftelse SEB.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Introduction

The risk for brain injury manifested as cerebral palsy is higher in very preterm born children than in term. Prenatal administration of magnesium sulfate (MgSO 4 ) has been shown to be neuroprotective and reduces the proportion of very preterm born children later diagnosed with cerebral palsy. A Swedish national clinical practice guideline was implemented in March 2020, stipulating the administration of a single intravenous dose of 6 g MgSO 4 1–24 h prior to delivery before gestational age 32+0, aiming for 90% treatment coverage. The aim of this study was to evaluate the feasibility of this new clinical practice guideline in the first year of its implementation. Material and methods Data on MgSO 4 treatment were collected by reviewing the medical charts of women who gave birth to live born children in gestational age 22+0–31+6 during the period of March 1, 2020 to February 28, 2021, at five Swedish university hospitals. Women with pre‐eclampsia, eclampsia, or high elevated liver enzymes low platelets (HELLP) were excluded.

Results

A total of 388 women were eligible and 79% received treatment with MgSO 4 . Of the 21% not receiving treatment, 9% did not receive treatment due to lack of knowledge about the clinical practice guideline, 9% were not possible to treat and 3% had missing data. The proportion treated increased from 72% to 87% from the first to the last 3 months. Of those treated, 81% received the drug within the stipulated timeframe (mean 8.7 h, median 3.4 h).

Conclusions

There was a positive trend over time in the proportion of women receiving MgSO 4 treatment, but the a priori target of 90% was not reached during the first year of implementation. Our findings indicate that this target could be reached with additional information to clinicians.

Subjects

MeSH terms (MEDLINE)

Premature BirthCerebral PalsyNeuroprotective AgentsPregnancyChildInfant, NewbornFemaleHumansAdultYoung AdultMagnesium SulfateNeuroprotectionFollow-Up StudiesFeasibility StudiesPrenatal Care

Author keywords

cerebral palsyextremely pretermmagnesium sulfateneuroprotectionpremature birthpreterm birthvery preterm

Substances

Magnesium SulfateNeuroprotective Agents

Authors and institutions

  • Department of Obstetrics and Gynecology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Division of Neonatology, Department of Pediatrics, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Center of Perinatal Medicine and Health, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
  • Clinical Intervention Science and Technology, CLINTEC, Karolinska Institute, Stockholm, Sweden.
  • Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

ORCID profiles: Sara Hellström, Maria Jonsson, Ylva Carlsson

Funding

  • Frimurarfonden Barnhusdirektionen Foundation
  • Linnea and Josef Carlsson Foundaton
  • Rune and Ulla Almlövs stiftelse SEB
  • Stiftelsen Mary von Sydows, född Wijk, donationsfond
  • Stiftelserna Wilhelm och Martina Lundgrens
  • The ALF Agreement
  • Vetenskapsrådet
  • The study was also financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (YC,…

Cite

APA

Hellström, S., Jonsdotter, A., Jonsson, M., Pettersson, K., Saltvedt, S., Herbst, A., Ågren, J., Ådén, U., Domellöf, M., Hagberg, H., & Carlsson, Y. (2023). A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.14673

Vancouver

Hellström S, Jonsdotter A, Jonsson M, Pettersson K, Saltvedt S, Herbst A, et al. A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth. Acta Obstetricia et Gynecologica Scandinavica. 2023. doi:10.1111/aogs.14673

BibTeX
@article{Hellstrm2023,
  author = {Hellström, Sara and Jonsdotter, Andrea and Jonsson, Maria and Pettersson, Karin and Saltvedt, Sissel and Herbst, Andreas and Ågren, Johan and Ådén, Ulrika and Domellöf, Magnus and Hagberg, Henrik and Carlsson, Ylva},
  title = {A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2023},
  doi = {10.1111/aogs.14673}
}
Start for free →